GenMark Diagnostics (GNMK) to Release Earnings on Thursday

Share on StockTwits

GenMark Diagnostics (NASDAQ:GNMK) is scheduled to issue its quarterly earnings data after the market closes on Thursday, February 21st. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Shares of GNMK opened at $6.10 on Thursday. The company has a market capitalization of $330.13 million, a PE ratio of -5.04 and a beta of 1.49. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.10 and a current ratio of 3.75. GenMark Diagnostics has a one year low of $3.58 and a one year high of $8.81.

In other GenMark Diagnostics news, insider Hany Massarany sold 5,884 shares of the company’s stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $5.08, for a total transaction of $29,890.72. Following the transaction, the insider now owns 666,999 shares of the company’s stock, valued at approximately $3,388,354.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott Mendel sold 5,297 shares of the company’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $5.90, for a total value of $31,252.30. Following the transaction, the chief financial officer now directly owns 235,777 shares in the company, valued at approximately $1,391,084.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,256 shares of company stock worth $232,260. Company insiders own 7.09% of the company’s stock.

GNMK has been the topic of several recent analyst reports. Canaccord Genuity reduced their target price on GenMark Diagnostics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 30th. Raymond James set a $7.00 target price on GenMark Diagnostics and gave the stock a “buy” rating in a report on Thursday, December 27th. Zacks Investment Research raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Finally, BidaskClub raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, January 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $9.50.

COPYRIGHT VIOLATION WARNING: “GenMark Diagnostics (GNMK) to Release Earnings on Thursday” was posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://weekherald.com/2019/02/14/genmark-diagnostics-gnmk-to-release-earnings-on-thursday.html.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Read More: Stochastic Momentum Index (SMI)

Earnings History for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply